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Abstract
The human pregnane X receptor (PXR) recognizes a range of structurally- and chemically-distinct
ligands and plays a key role in regulating the expression of protective gene products involved in the
metabolism and excretion of potentially harmful compounds. The identification and development of
PXR antagonists is desirable as a potential way to control the up-regulation of drug metabolism
pathways during the therapeutic treatment of disease. We present the 2.8 Å resolution crystal
structure of the PXR ligand binding domain (LBD) in complex with T0901317 (T1317), which is
also an agonist of another member of the orphan class of the nuclear receptor superfamily, the liver
X receptor (LXR). In spite of differences in the size and shape of the receptors' ligand binding pockets,
key interactions with this ligand are conserved between human PXR and human LXR. Based on the
PXR-T1317 structure, analogues of T1317 were generated with the goal of designing an PXR
antagonist effective via the receptor's ligand binding pocket. We find that selectivity in activating
PXR vs. LXR was achieved; such compounds may be useful in addressing neurodegenerative
diseases like Niemann-Pick C. We were not successful, however, in producing a PXR antagonist.
Based on these observations, we conclude that the generation of PXR antagonists targeted to the
ligand binding pocket may be difficult due to the promiscuity and structural conformability of this
xenobiotic sensor.
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Introduction
The human pregnane X receptor (PXR; alternatively SXR, PAR) responds to a variety of
endogenous and exogenous compounds in liver, intestine and other tissues, and is a key
regulator of the expression of genes central to xenobiotic metabolism and excretion 1-3. PXR
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is also responsible for an important class of drug interactions caused by the efficient up-
regulation of chemoprotective pathways that lead to the elimination of a wide range of
therapeutics 4-7. It has also recently been shown that T0901317 (T1317), the ligand described
here in complex with PXR, protects against the development of the neurodegenerative disease
Niemann-Pick C in a PXR-dependent fashion within a mouse model of this condition 8.
Like other members of the orphan class of the nuclear receptor (NR) superfamily, PXR contains
DNA-binding and ligand-binding domains (DBD, LBD, respectively), acts as a heterodimer
with the retinoid X receptor-α (RXRα), and binds to a range of direct- and everted-repeat
elements in the regulatory region of target genes 9. Upon association with an activating agonist,
a transcriptional coactivator protein like the steroid receptor coactivator-1 (SRC-1) is recruited
to the activation function-2 (AF-2) region of the PXR LBD, which facilitates changes in
chromatin structure and activation of the basal transcriptional machinery. A leucine-rich
LxxLL motif in transcriptional coactivators (where x is any amino acid) has been shown to
interact with a groove present in the active orientation of NR LBDs 10, 11. Crystal structures
of the human PXR LBD have been determined in complexes with a variety of small (e.g.,
SR12813, hyperforin) and large (e.g., rifampicin) ligands, and with fragments of the human
transcriptional coactivator SRC-1 12-15. These structures have revealed that PXR's ligand
binding promiscuity is a function of its large and conformable ligand binding pocket, which is
framed in part by sequence elements novel to PXR relative to other NR LBDs. In addition, the
PXR LBD forms a unique homodimer mediated by a tryptophan zipper-like motif, and it has
been shown that this interface plays a role in receptor function and association with coactivators
16.
The liver X receptor (LXR), another member of the orphan class of NRs that functions as a
heterodimer with RXRα, plays an important role in monitoring the levels of oxysterols in
hepatocytes and regulates the expression of genes essential for cholesterol homeostasis
17-21. The LBDs of the two LXR isoforms, α and β, both share 31% sequence identity with
the human PXR LBD (and 77% with one another), as well as the conserved overall structural
fold common to NR ligand binding domains 22-26. The PXR LBD deviates from that of LXR
in its ∼60-residue α1- α3 insert that adds one helix (α2) and two strands (β1, β1') and frame a
significantly larger ligand binding pocket relative to LXR 10. The synthetic NR ligand
T0901317 (T1317) is an established agonist for LXR, exhibiting robust upregulation of target
gene expression 19. The structural basis of T1317 binding to LXR isoform β has been
elucidated previously 22, 24, 26.
In addition to their association with transcriptional coactivators, NR LBDs bind to
transcriptional corepressors (e.g., NCoR, SMRT) that exert opposite effects on gene
transcription by mechanisms that include enhancing the condensed structure of chromatin 4.
Interactions between NRs and corepressors can occur in the absence of ligand, but are enhanced
in the presence of antagonizing ligands. A paradigm for this effect is provided by efficient
down-regulation of transcription caused by the association of the estrogen receptor (ER) with
the established antagonist tamoxifen. It has been shown structurally that corepressors contain
an extended leucine-rich region that binds to an inactive LBD conformation distinct in structure
from that of an active LBD, particularly in the position of the terminal α-helix in the LBD fold
(αAF in PXR) 27. In ER, tamoxifen sterically blocks the active orientation of the terminal helix
in that fold, producing a state that preferentially binds to transcriptional corepressors and down-
regulates gene expression 28. In the case of PXR, most ligands are found to act as agonists of
this receptor, in line with its established role in protecting tissues from potentially harmful
chemicals. A small number of antagonists have been described, however, including the ET-743
29 and the antifungal ketoconazole 30, 31. Indeed, ketoconazole has been shown recently to
repress the binding of both transcriptional coactivators and corepressors to PXR 30. The
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structural basis of the antagonism of PXR by these compounds has not been established,
however.
The identification or design of new antagonists of human PXR are desirable because of the
important role this receptor plays in drug metabolism, and because the current antagonists
exhibit weak EC50 values relative to established agonists 29-31. Repressing the ability of PXR
to recognize the presence of therapeutic compounds may allow lower doses to be administered
with higher efficacy and fewer side effects. Here we present the 2.8 Å resolution crystal
structure of the PXR LBD in complex with T1317. Using this structure as a guide, and inspired
by selective ER modulators produced from ER agonists, we generate T1317 analogues
designed to act as PXR antagonists by disrupting the active conformation of the receptor's
αAF. We find, however, that compounds based on this scaffold either retain their ability to
bind to PXR, and thus serve as agonists, or simply do not bind to the receptor. We conclude
that the design of effective pocket-targeted PXR antagonists may be difficult due to the
promiscuous and conformable nature of the receptor's ligand binding pocket.
Results
PXR-T1317 Structure
Crystals of the human PXR LBD were grown in the presence of 10-fold molar excess T0901317
(T1317), x-ray diffraction data to 2.8 Å resolution were collected, and the structure was
determined and refined to R and Rfree values of 0.216 and 0.279, respectively (Table I). Two
ternary complexes were observed in the asymmetric unit, each containing one human PXR
LBD, one orientation of bound T1317, and one fifteen amino acid stretch of the human
transcriptional coactivator steroid receptor coactivator 1 (SRC-1, residues 682-696) (Figure
1). The PXR LBD is expressed with an 88-amino acid fragment of SRC-1 (residue 623-710)
to improve protein stability. This is the first structure of PXR in which the coactivator fragment
remains attached during crystallization. The retention of this fragment is likely due to the
relatively high affinity and potent agonist activity of T1317. The 88-amino acid region of
human SRC-1 employed contains two leucine-rich NR box motifs (at 633-637, LVQLL, and
690-694. LHRLL). Only the second NR box was observed associated with the AF-2 region of
the PXR LBD in both molecules in the crystallographic asymmetric unit. This implies that the
sequence around or including LHRLL may have higher affinity for PXR relative to the region
around the LVQLL motif.
The PXR LBD in this T1317 complex retains the same overall structure observed in previous
PXR structures, sharing, for example, 1 Å root-mean-square deviation (rmsd) over Cα
positions with the structure of the apo (unliganded) PXR LBD 15. The LBDs also form a
homodimer consistently observed either via crystallographic or, as in this case, non-
crystallographic symmetry. This homodimer interaction is mediated largely by interdigitating
aromatic residues from β1' in each monomer, and its formation has been shown to be central
to transcriptional activity and coactivator recruitment by PXR 16. Only a small number of shifts
in the positions of amino acids that line the ligand binding pocket of PXR were observed
between the T1317 and apo structures. For example, Leu-209 and Met-323 undergo a rotamer
changes and shifts in position of 6.0 Å. It was also noted that the side chains of both His-407
and Phe-429 shift 1.0 Å toward the bound ligand relative to the apo structure, and in doing so
form an 3.8 Å aromatic edge-to-edge van der Waals contact (compared to 5.3 Å for the same
atoms in the apo structure). Because Phe-429 is located on the αAF of the PXR's AF-2 region,
this interaction likely stabilizes the active form of the receptor during the upregulation of gene
transcription.
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T1317 forms three polar and twelve van der Waals contacts with amino acid side chains that
line the PXR ligand binding pocket (Figure 2; Table II). His-407 is positioned 2.4 Å from the
ligand's hydroxyl group, while the polar groups of the Gln-285 side chain are 2.9 and 3.2 Å
from one sulfoxy oxygen and His-327 is 3.3 Å from the other. This is the first time His-327
has been observed within hydrogen bonding distance (generously defined) of a bound ligand
in any of the PXR complexes determined to date. Similarly, Tyr-306, which forms an edge-to-
face with the free benzyl ring of T1317, has also not been observed to contact ligand in previous
structures. The same T1317 benzyl ring forms parallel and edge-to-face aromatic stacking
interactions with Phe-288 and Trp-299, respectively. The two CF3 groups of the ligand form
van der Waals contacts with five residues, including a 3.5 Å interaction with Met-425 located
on the receptor's αAF that likely helps to stabilize the active conformation of the AF-2 surface.
The volume of the PXR ligand binding pocket in this structure was measured to be 1,334 Å3
and it was further found that the T1317 ligand occupied all but 442 Å3 of that space. In total,
the fifteen residues contacted by T1317 is the largest observed for a small ligand in PXR's
pocket, but does not exceed the eighteen residues contacted by the large macrolide antibiotic
rifampicin 12.
T1317 Binding by LXR vs. PXR
We next compared the structure of the human PXR LBD-T1317 complex to that of the human
LXRβ LBD complexed to the same ligand 22, 24-26. The LBDs exhibited the same overall
fold, sharing 2.2 Å rmsd over Cα positions (and 27% sequence identity), although the
secondary structural elements present on the α1- α3 insert novel to PXR, including β1, β1', and
α2, are not present in the LXR LBD (Figure 3). LXR's ligand binding pocket is roughly half
the size of PXR's (650 Å3) and the observed binding of T1317 within the pocket uses essentially
all the available space. The distinct and limited shape of the LXR pocket causes the T1317
ligand to bind in a position rotated by ∼30° and shifted by up to 5.3 Å relative to the position
observed in the PXR complex. Sixteen LXR side chains contact T1317, two of which form
hydrogen bonds with the ligand (His-435 and Thr-316). His-435 in LXR corresponds in both
sequence and structure to His-407 in PXR; however, Gln-285, which forms two polar contacts
with T1317 in the PXR complex, is replaced by a leucine in LXR (Table II, Figure 4). Thr-316,
which forms the second polar interaction in LXR, is related in sequence to Phe-288 in PXR,
but corresponds in structure to His-327, albeit shifted in position by ∼5.5 Å. The benzyl ring
of T1317 forms aromatic contacts with phenylalanines 271 and 329 in LXR, which helps to
position the ligand distinctly within the pocket when compared to PXR. It is also noted that
distinct histidine-aromatic interactions are observed in PXR relative to LXR. An edge-to-face
aromatic interaction between His-435 and Trp-457 had been noted previously for LXR; this
contact is replaced in PXR by a 3.8 Å edge-to-edge interaction between His-407 and Phe-429.
A second histidine aromatic contact is observed in PXR: a 3.3 Å face-to-edge interaction
between Trp-299 and His-327 (Figure 4). In total, PXR and LXR share one conserved polar
contact and eight conserved hydrophobic interactions in their respective complexes with T1317
(Table II). In addition, both receptors directly contact corresponding residues located on the
αAF helices of their AF-2 surfaces (Met-425 in PXR, Leu-453 in LXR). LXR apparently further
stabilizes its AF-2 region by the formation of the aromatic contact between His-435 and
Trp-457, which is located on αAF. Taken together, these observations show that, in spite of
differences in pocket shape and ligand orientation, numerous key contacts are conserved
between these related receptors, leading to the efficient upregulation of targets genes by T1317.
Design and Examination of Putative Antagonists
Because T1317 appears to bind particularly strongly to PXR, we next sought to design a PXR
antagonist using the T1317 structure as a scaffold. It is known that antagonists of other nuclear
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receptors (e.g., tamoxifen for the estrogen receptor) appear to function by sterically blocking
the active position of αAF 28. Thus, we chose to change the structure of the CF3-containing
moiety in T1317, which binds adjacent to αAF in PXR (Figure 2). Eleven analogues were
synthesized that included both smaller and larger groups at this position (Figure 5; Scheme 1).
These compounds, along with T1317, were tested for their ability to bind to PXR in an in
vitro ligand-competition assay, and to activate PXR-mediated transcription in transient
transfection assays in cultured cells (Table III). Compounds 2-5, which retained the hydroxyl
group and one CF3 group, all exhibited good binding to and activation of PXR. In contrast,
compounds 6 and 7, which retain the hydroxyl group but not a CF3, are poor binders and
activators of PXR. Similarly, compound 8, which contains a acetyl group, was the least
efficacious compound examined. These data support the importance of the hydrogen bond
donated by the T1317 hydroxyl group to the His-407 side chain in PXR, in particular the
electron withdrawing character of the CF3 groups that polarize the hydroxyl group and improve
its ability to share its hydrogen atom 25.
Compounds 9-12 were designed to include large adducts adjacent to the hydroxyl and CF3
groups, with the goal of sterically disrupting αAF position. We were surprised to find, however,
that each compound bound well to PXR and served as an effective agonist rather than an
antagonist (Table III). For example, the presence of cyclohexyl or benzyl rings (compounds
9, 10) were apparently accommodated by the receptor's ligand binding pocket. Indeed, even a
benzyl group contained on an extended and rigid two-methylene linker (compound 11) did not
disrupt either ligand binding or receptor activation. These observations suggest that the αAF
and AF-2 region of PXR is reasonably conformable and capable of accommodating larger
adducts than was previously appreciated. The structural basis of these effects may be based on
the mobile α2 region of PXR, which is present on a sequence insert unique to this receptor
relative to other members of the nuclear receptor superfamily. This stretch of the PXR LBD
structure has been observed to shift in position by several Å between different ligand-bound
complexes, and, in the case of the PXR structure bound to the large macrolide antibiotic
rifampicin, to become completely disordered 12-15. The large adducts placed in the T1317
scaffold in compounds 9-12 may be directed toward this region of PXR and may create space
for themselves by disrupting the position of α2 rather than αAF. In addition, they could extend
from the receptor's pocket into solvent by creating a pore adjacent to Leu-240 (Figure 2). In
either case, these observed effects underscore the fundamentally promiscuous nature of PXR
in terms of ligand binding – the receptor contains a polypeptide insert that allows its binding
pocket to expand and contract, facilitating the productive binding of a wide range of chemical
structures.
The activation of gene expression by T1317 analogues was also examined via LXRβ by
transient transfection assays in cultured cells (Table III). Similar to PXR, compounds 6-8,
which do not retain the hydroxyl-group proximal to a CF3 moiety, were poor ligands for LXR,
highlighting the importance of the His-435 hydrogen received from the polarized ligand
hydroxyl group. In contrast to PXR, however, compounds 9 and 11 were poor agonists of LXR,
while compounds 10 and 12 were relatively effective. Considering the structure of the LXRβ-
T1317 complex, the benzyl group in 10 may stack upon the aromatic Phe-268 side chain, an
interaction not possible with compounds 9 or 11. For 12, the flexible nature of its CF3-rich
extension may facilitate productive binding by protruding past Phe-268 into solvent. Taken
together, these observations regarding the impact of T1317 analogues on LXR-mediated gene
expression reveal that this receptor, with its smaller ligand binding pocket and more narrow
agonist profile, is more accommodating to changes in chemical structure than was expected.
This highlights the plasticity present in the conserved nuclear receptor LBD fold, particularly
for members of the former orphan class.
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T1317 is an efficacious activator of gene transcription mediated by both the nuclear receptors
PXR and LXRβ 19. We show, by comparing the 2.8 Å resolution crystal structure of the PXR-
T1317 complex to the LXRβ-T1317 complexes reported previously 22, 24-26, that these two
LBDs share some analogous contacts to the ligand, but exhibit key differences as well. The
packing of aromatic side chains against the benzyl group of T1317, as well as the distinct
placement of the proximal hydrogen-bonding residue Thr-316, cause the ligand to adopt a
position in LXR rotated ∼30° and shifted by ∼5 Å relative to that observed in PXR. Still, nearly
half the contacts between protein and ligand are conserved in both complexes, including the
close hydrogen bond between a histidine side chain and a polarized hydroxyl group of the
ligand. Both LBDs also utilize an interaction between the same histidine side chain and an
aromatic residue located on AF-helices of the receptors' AF-2 regions: Trp-457 in LXR and
Phe-429 in PXR. Indeed, it was noted in this PXR complex that the presence of the ligand
appears to mediate the formation of a direct 3.8 Å aromatic contact between these side chains
caused by their shift by 1 Å in position toward the bound T1317. It is likely that the additional
stabilization of the active conformation of αAF by this interaction plays in important role in
the control of gene expression by both nuclear receptors.
We were surprised both by the difficulty we experienced in designing an antagonist to either
receptor, and by the plasticity the LXR receptor exhibits upon derivatization of the efficacious
ligand T1317. Given the numerous interactions observed between the T1317 and the ligand
binding pockets of both receptors, it was expected that adding bulky groups to the region
adjacent to the hydroxyl and dual CF3 moieties on the ligand would produce compounds that
sterically block the active orientation of the AF-helix (as seen in the estrogen receptor with
tamoxifen, for example) 28. Instead, we found for PXR that compounds either bound and were
agonists, or appeared incapable of binding to the receptor. In addition, in the cases where
reasonably large groups were added to the T1317 scaffold, the region of PXR's ligand binding
pocket adjacent to αAF was remarkably amenable to accommodating bulky additional atoms.
This is perhaps not surprising for PXR, given its well established promiscuous ligand binding
character and the structural flexibility of unique regions (such as α2) in its ligand binding
pocket. It would appear that for PXR, in contrast to more rigid and specific steroid receptors
like the estrogen receptor, ligands can bridge between rigid portions of the pocket, while more
flexible regions of the protein can shift to accommodate a variety of distinct chemical
structures.
While the promiscuity of PXR is well known, we were not expecting to find that LXRβ would
also show evidence for conformability in accommodating larger T1317 analogues. For
example, compounds 10 and 12 were relatively effective agonists for LXR, in spite of the
presence of large groups attached adjacent to T1317's hydroxyl moiety (Figure 5). The
structural basis of this is likely centered on the region around Phe-268 in the LXR pocket,
which may stack with the aromatic group in 10 and provide a pore for the conformable group
in 12. LXR did exhibit more specificity for the types of groups it can accommodate in this
position relative to PXR, however, as non-aromatic or longer rigid adducts in 9 and 11,
respectively, that still activated PXR were clearly not agonists for LXRβ. Thus, the ligand
binding domains of numerous members of the nuclear receptor superfamily, particularly the
former orphan receptors, are likely to posses some degree of structural flexibility to assist in
the accommodation of chemically-distinct ligands. It would appears that PXR, though, with
its large and mobile α1-α3 insert, is at the extreme of this flexibility continuum with these
unique features that are central to its significant promiscuity.
We conclude that the unique aspects of the PXR ligand binding pocket may make antagonist
design particularly difficult for this member of the nuclear receptor superfamily. It is noted
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that compounds 9 and 11 appear to be selective for PXR relative to LXRβ; as such, they may
be useful as leads to address neurodegenerative diseases like Niemann-Pick C 8. However, it
may be necessary to look outside the ligand binding pocket of PXR to find sites effective at
antagonizing the receptor using small molecules. Candidate sites on the LBD include the AF-2
surface 30 and the PXR homodimer interface, the disruption of which has been shown to impact
productive coactivator binding by the receptor 16. An effective PXR antagonist, if identified,
may be of significant clinical use to reduce the activation of xenobiotic metabolism pathways
during the therapeutic treatment of disease.
Materials and Methods
Protein Expression and Purification
Generation of human PXR LBD in complex with the 88-amino acid fragment of human SRC-1
was accomplished as described previously 12-16. To prevent the formation of covalent
complexes with reducing agent during crystallization, as has been seen with previous structures
(data not shown), Cys-284 within the ligand binding pocket of the human PXR LBD was
replaced with serine.
Crystallization
The human PXR ligand-binding domain/SRC-1 complex (hPXRLBD/SRC-1) was
concentrated in the presence of 10-fold molar excesses T0901317 (T1317; synthesized in-
house) to a final concentration of 5 mg/mL. Crystallization was achieved by hanging-drop
vapor diffusion against the following conditions at 22 °C: 50 mM imidazole at pH 7.1, 10%
2-propanol, v/v.
Data Collection and Structure Determination
The structure of the T1317-bound form of the ligand binding domain of human PXR was
determined by molecular replacement using the crystal structure of the apo (unliganded) PXR
as a search model 15. Rotation and translation function searches were performed using AMoRe
32; clear solutions for each monomer of the dimer in the asymmetric unit were obtained in the
proper space group, P212121. The structure was refined using CNS with the maximum
likelihood function as a target, and included an overall anisotropic B-factor and a bulk solvent
correction 33. Ten percent of the observed data were set aside for cross-validation using the
free-R statistic prior to any structural refinement 34. Manual adjustments and building of the
model (including the placement of the T0901317 ligands and SRC-1 coactivator fragments)
were performed using O 35 and σA-weighted electron density maps 36. The structure exhibits
good geometry (Table I) with no Ramachandran outliers.
Compound Syntheses
See Scheme 1 for steps involved in compound generation. 1H-NMR spectra were recorded on
a Varian Gemini 400 MHz NMR spectrometer. 1H-NMR spectra are reported as chemical shift
δ, number of protons, multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet; br s, broad
singlet) and coupling constant (J) in Hertz. Electron Spray (ES) or Chemical Ionization (CI)
was recorded on a Hewlett Packard 5989A mass spectrometer. Mass spectrometry results are
reported as the mass over charge. Purity by HPLC [Luna 20 × 4 mm 3.0 micron C18(2) column,
water (+0.1% v/v formic acid)/MeOH (+0.075% v/v formic acid) gradient: 50% MeOH to 100
% MeOH for 5 minutes, holding at 100% MeOH for final 1 minute, flow rate = 2.0 mL/min].
Starting material are either available from commercial sources or via literature procedures.
Abbreviations used in the examples below have their accepted meanings in the chemical
literature. For example, DCM (dichloromethane), THF (tetrahydrofuran), MeCN (acetonitrile),
DMSO (dimethylsulfoxide) and TBAF (tetrabutylammonium fluoride).
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Compound 6: 4-Aminobenzyl alcohol (10 g, 80 mmol) and benzenesulfonyl chloride (11.5
mL, 89 mmol) in pyridine were heated at 60°C overnight. Water was added and extracted with
DCM. The organic layer was separated and evaporated to dryness. The residue was purified
by silica gel chromatography using ethyl acetate to give 17 g (80%) of intermediate
sulfonamide: 1H-NMR (DMSO-d6) δ: 7.8 (s, 1H), 7.65 (m, 3H). 7.10 (d, J=8.8Hz, 2H), 7.01
(d, J=8.8Hz, 2H), 5.04 (br s, 1H), 4.45 (s, 2H). The intermediate sulfonamide (1.2 g, 4.6 mmol),
2,2,2-trifluoroethyltrifluoro-methane sulfonate (1.97 g, 9.1 mmol) and K2CO3 (1.25 g, 9.1
mmol) in MeCN (20 mL) was heated at 80°C overnight. The solvents were removed under
reduced pressure. The residue was purified by silica gel chromatography using 50% ethyl
acetate in hexanes to give 6 (1.0 g, 80%): 1H-NMR (DMSO-d6) δ: 7.5-7.8 (m, 5H), 7.26 (d,
J=8.5 Hz, 2H), 6.99 (d, J=8.5 Hz, 2H), 5.30 (br s, 1H), 4.62 (m, 2H), 4.43 (s, 2H); LC/MS (ES
+): m/e 346 (M+H), 100% purity.
Compound 8: Prepared in a similar fashion from 4-aminoacetophenone (5.0 g, 37.0
mmol): 1H-NMR (DMSO-d6) δ: 7.90 (d, J=8.4 Hz, 2H), 7.56-7.71 (m, 5H), 7.27(d, J=8.4 Hz,
2H), 4.64 (m, 2H), 2.48 (s, 3H), LC/MS (ES+) m/e 358 (M + H), 95% purity)
Compound 2: DMSO (5.5 mL, 28 mmol) was added dropwise to 2M oxalyl chloride in DCM
(19 mL)at −78°C under nitrogen followed by sequential addition of compound 6 (10 g, 30
mmol) in DMSO:DCM (1:1) (20 mL) and neat triethylamine (75 mL). The reaction mixture
was gradually warmed to room temperature overnight whereupon the solvents were removed
under reduced pressure. The residue was purified by silica gel chromatography with DCM to
give an intermediate aldehyde (8.5 g, 85%): 1H-NMR (DMSO-d6) δ: 9.8 (s, 1H), 7.8 (m, 2 H),
7.52-7.81 (m, 5H), 7.38 (m, 2H).
The intermediate aldehyde (5.0 g, 14.6 mmol) and trifluoromethyltrimethylsilane (2.5 g, 17.5
mmol) in anhydrous THF (15 mL) was treated with a catalytic amount of TBAF at 0°C. The
reaction mixture was gradually warmed to room temperature overnight. The reaction mixture
was treated with 1N hydrochloric acid at room temperature for 1h. Water was added and
extracted with DCM. The organic layer was separated and evaporated to dryness. The residue
was purified by silica gel chromatography using 20% ethyl acetate in hexanes to give 2 (5.0
g, 85%): 1H-NMR (MeOH-d4) δ: 7.65 (m, 1H), 7.58 (d, J=8.6 Hz, 2 H), 7.52 (m, 2H), 7.45 (d,
J=8.2 Hz, 2H), 7.11 (d, J=8.6 Hz, 2H), 5.03 (m, 1H), 4.43 (m, 2H); LC/MS (ES+) m/e 414 (M
+H), 96% purity.
The following compounds were prepared in an analogous fashion:
Compound 12: Treatment of intermediate aldehyde with heptafluoropropyl-trimethylsilane
(0.06 mL, 0.29 mmol) and purification by reverse phase chromatography on RP-C18 with
50-100% MeCN in water provided compound 12 (20 mg, 15%) as a racemic mixture: 1H-NMR
(MeOH-d4) δ: 7.72 (m, 3H), 7.52 (m, 4H) 7.17 (d, J=8.6 Hz, 2H), 4.41 (m, 2H), 2.22 (m, 1H),
1.99 (m, 1H), 1.38 (m, 2H), 0.91 (m, 3H); LC/MS (ES+) m/e 456 (M+H), 98% purity.
Compound 3: Compound 3 was prepared in an analogous fashion from compound 8 to given
30 mg (25%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.49-7.65 (m, 7H), 7.10 (d, J=8.6
Hz, 2H), 4.40 (m, 2H), 1.70(s, 3H), LC/MS (ES+) m/e 428 (M + H), 98% purity.
Compound 4: Compound 2 (2.5 g, 6.0 mmol), Dess-Martin periodinane (5.2 g, 12.0 mmol)
and pyridine (4mL, 48 mmol) in DCM (60 mL) was stirred at room temperature overnight.
The reaction was treated with 60 mL of an aqueous solution of NaHCO3:Na2S2O3 (5:1) and
stirred at room temperature for 2 h. The organic layer was separated and evaporated to dryness.
The residue was purified by silica gel chromatography using 50% ethyl acetate in hexanes to
give an intermediate trifluoromethyl ketone (2.2 g, 90%): 1H-NMR (MeOH-d4) δ: 7.46-7.62
(m, 7H), 7.21 (d, J=8.6 Hz, 2H), 4.45 (m, 2H). 1M ethyl magnesium bromide in THF (0.5 mL)
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was slowly added to a solution of the above ketone (100 mg, 0.24 mmol) in THF (3mL) at
−78°C. The reaction mixture was gradually warmed to room temperature overnight. Saturated
aqueous NH4Cl was added, and the aqueous layer was extracted with ethyl acetate. The organic
layer was separated and evaporated to dryness. The residue was purified by reverse phase
chromatography on RP-C18 using 50-100% MeCN in water to give 4 (5 mg, 10%) as a racemic
mixture: 1H-NMR (MeOH-d4) δ: 7.54-7.71 (m, 7H), 7.11 (d, J=8.6Hz, 2H), 4.45 (m, 2H), 2.21
(m, 1H), 1.98 (m, 1H), 0.87 (m, 3H); LC/MS (ES+) m/e 445 (M+H), 98% purity.
The following compounds were prepared in an analogous fashion from the above intermediate
trifluoromethyl ketone:
Compound 5: Using 2M n-propyl magnesium bromide in diethyl ether followed by
purification by reverse phase chromatography on RP-C18 with 50-100% MeCN in water gave
rise to compound 5 (7 mg, 10%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.47-7.65 (m,
7H), 7.11 (d, J=8.6 Hz, 2H), 4.41 (m, 2H), 2.22 (m, 1H), 1.99 (m, 1H), 1.38 (m, 2H), 0.91 (m,
3H); LC/MS (ES+) m/e 456 (M+H), 95% purity.
Compound 9: Using 2M cyclohexyl magnesium bromide in diethyl ether (0.13 mL) followed
by purification by reverse phase chromatography on RP-C18 with 50-100% MeCN in water
provided compound 9 (20 mg, 20%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.43-7.89
(m, 7H), 7.11 (d, J=8.6 Hz, 2H), 4.41 (m, 2H), 2.61-2.05 (4m, 5H), 1.03 (m, 3H), 0.93 (m, 3H);
LC/MS (ES+) m/e 496 (M+H), 94% purity.
Compound 10: Using 3M phenyl magnesium bromide in diethyl ether (0.09 mL) followed by
purification via reverse phase chromatography on RP-C18 with 50-100% MeCN in water gave
rise to compound 10 (70 mg, 70%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.33-7.69
(m, 12H), 7.11 (d, J=8.5 Hz, 2H), 4.42 (m, 2H), LC/MS (ES+) m/e 490 (M+H), 100% purity.
Compound 11: To a solution of phenylacetylene (83 mg, 0.75 mmol) in THF (2 mL) was
added 1.6M n-BuLi in hexanes (0.315 mL, 0.5 mmol) at −78°C over 30 minutes. After this
time, a solution of the above intermediate trifluoromethylketone (100 mg, 0.25 mmol) in THF
(2 mL) was added. The reaction mixture was gradually warmed to room temperature overnight.
Saturated aqueous NH4Cl was added, and the aqueous layer was extracted with DCM. The
organic layer was separated and evaporated to dryness. The residue was purified by reverse
phase chromatography on RP-C18 using 50-100% MeCN in water to give compound 11 (77
mg, 75%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.43-7.80 (m, 12H), 7.17 (d, J=8.6
Hz, 2H), 4.42 (m, 2H); LC/MS (ES+) m/e 514 (M + H), 98% purity.
Compound 7: Compound 7 was prepared from 8 (100 mg, 0.28 mmol) and 1M vinyl
magnesium bromide (0.84mL, 0.84 mmol) using the procedure described for the preparation
of 4. Purification by reverse phase chromatography on RP-C18 using 50-100% MeCN in water
provided 7 (30 mg, 30%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.49-7.67 (m, 5H),
7.32 (d, J=8.4 Hz, 2H), 7.03 (d, J=8.4 Hz, 2H), 4.79 (m, 1H), 4.39 (m, 2H), 1.40(s,2H); LC/
MS (ES+) m/e 358 (M +H), 98% purity.
Transient Transfections
Transient transfection and reporter gene assays using full-length human PXR and LXRβ were
performed as described previously 12.
Competition Ligand Binding Assay
Competitive ligand binding assays using [N-methyl-3H]-GW0438X were preformed as
described elsewhere 16.
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Crystal structure of the homodimer in the asymmetric unit of the ligand binding domain of
human PXR (PXR LBD) in complex with T0901317 (T1317). The PXR LBD in one monomer
is rendered in red, yellow and green, and in the other monomer in cyan, magenta and pink. The
fragments of the steroid receptor coactivator 1 (SRC-1) are shown in aqua and orange, and the
T1317 ligands in magenta and green.
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Stereoview of the binding of T0901317 within the ligand binding pocket of the human PXR
LBD. Residues making polar contacts are rendered in green, those making hydrophobic
interactions are in red, with Met-425 from αAF highlighted in yellow.
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Superposition of the human PXR LBD monomer (red) on that of the human LXRβ LBD (gold),
with the T0901317 ligands present in both structures shown in magenta for PXR and blue for
LXR.
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Stereoview comparing the binding of T0901317 to the LBDs of human PXR and LXRβ. Human
PXR residues and T1317 ligand are colored as in Figure 1B, except Phe-429 and Met-243,
which are shown in white. In LXR, residues forming polar ligand contacts are shown in cyan,
while those forming hydrophobic interactions are in gold or, for Leu-452 and Tyr-335, in pink.
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Structures of analogues of T0901317 (compound 1) examined for their impact on human PXR
and human LXRβ.
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Reaction conditions: (a) benzenesulfonyl chloride, pyridine, 60°C; (b) 2,2,2-trifluoroethyl
trifluoromethylsulfonate, K2CO3, MeCN, 80°C; (c) oxalyl chloride, DMSO, Et3N, rt; (d)
trifluoromethyltrimethylsilane, TBAF, THF, 50°C; (e) Dess-Martin periodinane, pyridine,
DCM, rt; (f) RMgBr, THF, −78°C to rt; (g) phenylacetylene, n-BuLi, THF, −78°C to rt; (h)
vinylmagnesiun bromide, THF, −78°C to rt.
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Table I
Crystallographic Statistics for the PXR-T0901317 Complex
Resolution (Å; highest shell) 50-2.8 Å (2.9-2.8)
Space Group P212121
Asymmetric Unit two molecules
Cell Constants (Å, °) a = 83.9 b = 90.6
c = 105.7
α = β = γ = 90
Data Collection Facility SER-CAT (APS)
Total Reflections 119,110
Unique Reflections 20,332
Mean Redundancy (highest shell) 5.8 (5.4)
Rsym
* (%; highest shell) 13.5 (46.7)
Completeness (%; highest shell) 97.6 (91.1)






Rsym = Σ|I-<I>| / ΣI, where I is the observed intensity and <I> is the average intensity of multiple symmetry-related observations of that reflection.
†
Rcryst = Σ∥Fobs|-|Fcalc∥ / Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure factors, respectively.
‡
Rfree = Σ∥Fobs|-|Fcalc∥ / Σ|Fobs| for 10% of the data not used at any stage of structural refinement.
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Table II
Comparison of Residues Contacting T0901317 in PXR and LXR. Amino acids forming hydrogen bonding
interactions with ligand are listed in bold, those on the terminal αAF helices of the receptors are underlined, and























Residues 209 and 211 are on a sequence insert novel to PXR; thus, no equivalent side chains exist in LXR.
†
Cys-284 was mutated to serine to improve the crystallization behavior of PXR; see Materials and Methods.
‡
While Cys-301 corresponds in sequence to Phe-329, the PXR side chain Phe-288 overlaps structurally with this LXR phenylalanine; see Figure 4.
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